BioAtla, Inc. (BCAB)
1.71
+0.48
(+39.02%)
USD |
OTCM |
Oct 23, 16:00
BioAtla Enterprise Value : 7.163M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 7.163M |
| October 22, 2026 | 6.365M |
| October 21, 2026 | 6.574M |
| October 20, 2026 | 6.531M |
| October 19, 2026 | 6.498M |
| October 16, 2026 | 6.581M |
| October 15, 2026 | 6.481M |
| October 14, 2026 | 6.481M |
| October 13, 2026 | 6.448M |
| October 12, 2026 | 6.398M |
| October 09, 2026 | 6.814M |
| October 08, 2026 | 6.897M |
| October 07, 2026 | 6.964M |
| October 06, 2026 | 6.564M |
| October 05, 2026 | 6.515M |
| October 02, 2026 | 6.498M |
| October 01, 2026 | 6.415M |
| September 30, 2026 | 6.481M |
| September 29, 2026 | 6.581M |
| September 28, 2026 | 6.847M |
| September 25, 2026 | 6.781M |
| September 24, 2026 | 6.847M |
| September 23, 2026 | 6.964M |
| September 22, 2026 | 7.263M |
| September 21, 2026 | 7.512M |
| Date | Value |
|---|---|
| September 18, 2026 | 7.296M |
| September 17, 2026 | 7.479M |
| September 16, 2026 | 8.311M |
| September 15, 2026 | 6.598M |
| September 14, 2026 | 6.764M |
| September 11, 2026 | 6.814M |
| September 10, 2026 | 6.282M |
| September 09, 2026 | 6.365M |
| September 08, 2026 | 6.415M |
| September 04, 2026 | 6.515M |
| September 03, 2026 | 6.481M |
| September 02, 2026 | 6.323M |
| September 01, 2026 | 6.115M |
| August 31, 2026 | 7.13M |
| August 28, 2026 | 7.205M |
| August 27, 2026 | 9.542M |
| August 26, 2026 | 9.508M |
| August 25, 2026 | 9.741M |
| August 24, 2026 | 9.775M |
| August 21, 2026 | 9.608M |
| August 20, 2026 | 9.608M |
| August 19, 2026 | 9.758M |
| August 18, 2026 | 9.608M |
| August 17, 2026 | 9.409M |
| August 14, 2026 | 9.459M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.452M |
| Revenue (Quarterly) | 6.50M |
| Total Expenses (Quarterly) | 6.048M |
| EPS Diluted (Quarterly) | 0.272 |
| Profit Margin (Quarterly) | 6.95% |
| Earnings Yield | -1.49K% |
| Normalized Earnings Yield | -1507.75 |